english.prescrire.org > Spotlight > Archives : 2024 > Efgartigimod alfa (Vyvgart°) in generalised myasthenia gravis

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2024 : 1 | 30 | 60

Efgartigimod alfa (Vyvgart°) in generalised myasthenia gravis

 Marketing Authorisations   Efgartigimod alfa, an antibody Fc fragment that is claimed to increase IgG degradation by blocking the neonatal Fc receptor, has been authorised in the European Union as an add-on treatment in adults with generalised myasthenia gravis who have autoantibodies directed against acetylcholine receptors. Is efgartigimod alfa more effective at alleviating the symptoms of the disease than the other treatments proposed in this situation, does it prevent the complications of the disease, including myasthenic crisis, and what are its adverse effects?
Full article available for download by subscribers (3 pages)

©Prescrire 1 May 2024

Source: "Efgartigimod alfa (Vyvgart°) in generalised myasthenia gravis" Prescrire Int 2024; 33 (259): 121-123. Subscribers only.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter
 
See also:

"Ravulizumab (Ultomiris°)
in generalised myasthenia
gravis"
Prescrire Int 2024;